© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
January 28, 2022
Future opportunities being explored in clinical trials that show promise in treating advanced endometrial cancer.
What patients can expect in terms of prognosis when receiving systemic therapy for advanced endometrial cancer.
Recommendations on how to best prepare patients for chemotherapy, lenvatinib plus pembrolizumab, and other therapies used to treat advanced endometrial cancer.
Variables that impact choice of therapy for patients with advanced endometrial cancer.
The rationale for using systemic therapy to treat patients with advanced endometrial cancer.
A discussion on risk factors associated with endometrial cancer and the role of molecular testing to help evaluate for mismatch repair abnormality.